Alantra Private Equity buys three genetic diagnosis companies

Eugenia Jiménez
Alantra Private Equity buys three genetic diagnosis companies

Alantra Private Equity has acquired and integrated three Spain-headquartered genetic diagnostic companies Imegen, Genycell Biotech and Health in Code. The agreement contemplates that the management teams of the three companies will maintain significant stakes in the new group and will continue leading the management of the company, which will be the Spanish leader in the genetic diagnosis sector. In addition, the key shareholders of the three companies will reinvest in the new group, showi...

To continue reading this article...

Join International Investment

Join International Investment today

Unlock members-only benefits:

  • Unlimited access to real-time news, industry insights, video features and market intelligence
  • Stay ahead of the curve with spotlights on international financial centres, regional trends international advice and global industry leaders
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Hear the latest cross jurisdictional developments in wealth planning, tax, regulation, investing, retirement and protection
  • Members-only access to the Editor’s weekly news roundup newsletter
  • Members-only access to analysis via our exclusive industry polls
  • Be the first to hear about our events and awards programmes

Join now


Already a International Investment member?


Eugenia Jiménez
Author spotlight

Eugenia Jiménez

Eugenia Jiménez speaks Spanish and is Iberia Correspondent for Investment Europe covering Spain & Portugal, as well as Italy.